cydy

Newsmakers

CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020

May 13, 2020 admin Comments Off on CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020

VANCOUVER, Washington, May 13, 2020 — CytoDyn Submits Requested Datasets to FDA for Biologics License Application CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist […]

Healthcare

CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

April 30, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, Apr 30, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

April 13, 2020 admin Comments Off on CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

VANCOUVER, Washington, Apr 13, 2020  — More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more […]

Healthcare

CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

March 31, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

VANCOUVER, Washington, Mar 31, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

March 31, 2020 admin Comments Off on FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

(OTC: CYDY) Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

March 30, 2020 admin Comments Off on (OTC: CYDY) Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

VANCOUVER, Washington, Mar 30, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that an […]

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

March 27, 2020 admin Comments Off on CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]

Healthcare

(OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

March 27, 2020 admin Comments Off on (OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which […]

Healthcare

Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s (OTC: CYDY) Leronlimab, Bringing the Total to Four Patients

March 23, 2020 admin Comments Off on Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s (OTC: CYDY) Leronlimab, Bringing the Total to Four Patients

VANCOUVER, Washington, Mar 23, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab

March 19, 2020 admin Comments Off on U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab

A leading academic medical center has administered the test medication, leronlimab, in two of their sickest COVID-19 patients. Neither patient has had any serious adverse reactions to leronlimab since it was administered. We are hopeful […]

Newsmakers

CytoDyn (OTC: CYDY) Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

March 9, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

VANCOUVER, Washington, Mar 09, 2020  — Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn’s Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory […]

Healthcare

CytoDyn (OTC: CYDY) Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol

March 4, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol

VANCOUVER, Washington, Mar 04, 2020 CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of […]